All data are based on the daily closing price as of September 6, 2024
t
Torii Pharmaceutical
4551.TSE
25.47 USD
0.07
+0.28%
Overview
Last close
25.47 usd
Market cap
715.88M usd
52 week high
29.37 usd
52 week low
22.43 usd
Target price
30.58 usd
Valuation
P/E
19.4551
Forward P/E
N/A
Price/Sales
1.785
Price/Book Value
0.8484
Enterprise Value
410.67M usd
EV/Revenue
1.0206
EV/EBITDA
7.8256
Key financials
Revenue TTM
402.39M usd
Gross Profit TTM
164.34M usd
EBITDA TTM
49.93M usd
Earnings per Share
1.31 usd
Dividend
N/A usd
Total assets
835.52M usd
Net debt
-202.95M usd
About
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.